A specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Auxilium has been selling off lately likely due to pessimism about the launch of Xiaflex. Do I have an inside track on the issues of usage and reimbursement? Unfortunately not. But I don't believe the drop in share price indicates that anyone else does either. With Testim revenues still increasing and the jury still out on Xiaflex I believe the risk/reward profile has swung towards green.